Conference Call and Webcast Information:
Date:
Participant Dial-In (
Participant Dial-In (International): 1-201-389-0912
Conference ID: 13763643
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.
The company’s lead drug candidate is NXP100 (ciprocopan), a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.
NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.
NXP900 is an oral, small molecule inhibitor of the SRC family kinases, including SRC and YES1.
Company Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact:
Kevin Gardner
LifeSci Advisorskgardner@lifesciadvisors.com
Source: Nuvectis Pharma, Inc.
